MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/72/0.1/20.09.24 | Market Closed - Börse Stuttgart 10:22:18 10/06/2024 pm IST | ||
| 0.011 EUR | 0.00% |
|
| 3 months | -69.44% | ||
| 6 months | -70.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 0.011 | 0.00% |
| 07/24/07 | 0.011 | -8.33% |
| 06/24/06 | 0.012 | +9.09% |
| 05/24/05 | 0.011 | -8.33% |
| 04/24/04 | 0.012 | +9.09% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 10:22 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME48BG |
| ISIN | DE000ME48BG6 |
| Date issued | 28/11/2023 |
| Strike | 72 $ |
| Maturity | 20/09/2024 (102 Days) |
| Parity | 10 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.053 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.029 € |
| Spread % | 72.50% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Warrants
- Warrant
